Oseltamivir Dosing and Administration Guidelines

Treatment Dosing

• Adults and adolescents (≥ 13 years): 75 mg orally twice daily for 5 days. 1
• Children (≥ 1 year) – weight‑based:
  
  • < 15 kg: 30 mg twice daily
  • 15–23 kg: 45 mg twice daily
  • 23–40 kg: 60 mg twice daily
  • > 40 kg: 75 mg twice daily
  • (All weight categories supported by pediatric dosing recommendations.) 1
• Infants 3–12 months: 3 mg/kg per dose twice daily. 1
• Infants 3–12 months – age‑based when weight unknown:
  
  • 3–5 months: 20 mg twice daily
  • 6–11 months: 25 mg twice daily
  • (Age‑based regimens provided for situations lacking weight data.) [2][3]
• Infants < 3 months: 3 mg/kg per dose twice daily (treatment only). 1
• Infants < 3 months – age‑based when weight unknown: 12 mg twice daily. 4
• Premature infants: Standard weight‑based dosing is not recommended because of immature renal function; limited data show higher drug concentrations with 1.7 mg/kg twice daily and high variability. Consultation with pediatric infectious‑disease specialists is advised for extremely preterm infants (< 28 weeks). [4][2]5

Prophylaxis Dosing

• Adults and adolescents (≥ 13 years): 75 mg orally once daily for at least 10 days after close‑contact exposure (extend up to 6 weeks during community outbreaks). 1
• Children (≥ 1 year) – weight‑based (once daily):
  
  • < 15 kg: 30 mg
  • 15–23 kg: 45 mg
  • 23–40 kg: 60 mg
  • > 40 kg: 75 mg
  • (Same weight categories as treatment, but administered once daily.) 1
• Infants 3–12 months: 3 mg/kg once daily. 1
• Infants < 3 months: Prophylaxis not recommended unless the situation is judged critical because of limited safety and efficacy data. 1

Renal Dose Adjustment (Creatinine Clearance 10–30 mL/min)

• Treatment: 75 mg once daily for 5 days (instead of twice daily). 1
• Prophylaxis: Either 30 mg once daily or 75 mg every other day for the 10‑day post‑exposure period. 1
• End‑stage renal disease (hemodialysis or continuous peritoneal dialysis): No dosing recommendations are available. 4

Formulations and Administration

• Available capsule strengths: 30 mg, 45 mg, 75 mg. 1
• Oral suspension: Reconstituted to a final concentration of 6 mg/mL (updated from the previous 12 mg/mL formulation). 6
• If suspension unavailable: Capsules may be opened and the contents mixed with a sweetened liquid (e.g., chocolate syrup, corn syrup, caramel topping, or light brown‑sugar solution) to improve palatability. 1
• Compounded emergency suspension: Pharmacies can prepare suspension from 75 mg capsules to achieve a final concentration of either 15 mg/mL or 6 mg/mL. 1

Antiviral Resistance

• Since September 2009, 65 confirmed cases of 2009 H1N1 influenza resistant to oseltamivir have been reported. 1
• In surveillance of pandemic H1N1 viruses during 2014‑2015, 1.6 % demonstrated resistance to oseltamivir. 7

Clinical Indications for Treatment

• Hospitalized children with presumed influenza infection. 4
• Children at high risk for severe disease when influenza vaccination is contraindicated. 4
• Children at high risk during the two weeks following influenza vaccination. 4
• Patients with severe influenza (including those requiring intensive care). [7][5]

Oseltamivir Prophylaxis Guidelines

Dosing Recommendations for Healthy Populations

• Adults and adolescents ≥ 13 years: 75 mg orally once daily for a minimum of 10 days after close‑contact exposure; dosing may be extended up to 6 weeks during community outbreaks. 8, 9
• Children ≥ 1 year (weight‑based):
   < 15 kg → 30 mg once daily
   15–23 kg → 45 mg once daily
   23–40 kg → 60 mg once daily
   > 40 kg → 75 mg once daily
  Duration: 10 days post‑exposure, extendable to 6 weeks in outbreak settings. 8, 9
• Infants 3–12 months: 3 mg/kg once daily for 10 days. 8, 9

Special Populations

• Infants < 3 months: Routine prophylaxis is not recommended because of limited safety data; if treatment is required, use 3 mg/kg twice daily (treatment dose). 8, 9
• Premature infants: Standard weight‑based dosing is discouraged due to immature renal function; consultation with pediatric infectious‑disease specialists is advised, especially for infants < 28 weeks gestation. 8, 9

Renal Impairment Adjustments

• Creatinine clearance 10–30 mL/min:
  Option 1: 30 mg once daily for 10 days.
  Option 2: 75 mg every other day for 10 days (total 5 doses). Both regimens provide flexibility based on tolerance. 8, 9

Alternative Antiviral Options for Prophylaxis

• Zanamivir (inhaled): 10 mg (two 5‑mg inhalations) once daily for 10 days in adults and children ≥ 5 years. Not recommended for patients with underlying airway disease (asthma, COPD) because of bronchospasm risk; requires proper inhaler technique. 8, 9, 10
• Baloxavir marboxil: Approved only for treatment in patients ≥ 12 years; not FDA‑approved for prophylaxis. 8, 9
• Peramivir: Not recommended for prophylaxis; approved solely for treatment. 8, 9

Formulation and Administration

• Oral suspension: Reconstituted to a final concentration of 6 mg/mL. 8, 9
• Administration advice: Oseltamivir may be taken with or without food; taking it with meals can improve gastrointestinal tolerability. 8, 9

Duration Recommendations

• Standard post‑exposure prophylaxis: 10 days is the guideline recommendation. 8, 9
• CDC guidance: 7 days for routine prophylaxis; extend to 10 days when used as part of an institutional outbreak response. 8, 9

Oseltamivir (Tamiflu) Prophylaxis Dosing in Children

Weight‑Based Dosing (Children ≥ 1 year)

• The American Academy of Pediatrics (AAP) and the U.S. Food and Drug Administration (FDA) recommend a once‑daily, weight‑stratified prophylaxis regimen: ≤15 kg → 30 mg; 15.1–23 kg → 45 mg; 23.1–40 kg → 60 mg; >40 kg → 75 mg. [​11]

Infant Dosing (3–11 months)

• For infants aged 3–11 months, the AAP advises a prophylactic dose of 3 mg/kg once daily. [​11]

Infants < 3 Months – Contraindication

• Prophylaxis is not recommended for infants younger than 3 months because safety and efficacy data are insufficient; the AAP and the Centers for Disease Control and Prevention (CDC) explicitly advise against routine prophylaxis in this age group. [​11]

Premature Infants

• Standard weight‑based dosing is contraindicated in premature infants due to immature renal function and unpredictable drug accumulation; for extremely preterm infants (<28 weeks gestation) the AAP recommends consultation with a pediatric infectious‑disease specialist before prescribing. [​11]

Formulation and Administration

• The preferred formulation for children who cannot swallow capsules is the 6 mg/mL oral suspension; a 45 mg dose is administered as 7.5 mL of suspension. [​11]

Duration of Prophylaxis

• The 2025 AAP guideline specifies a standard post‑exposure prophylaxis duration of 7 days after the last known exposure; the FDA label permits up to 10 days, institutional outbreak protocols may extend to 10 days, and community outbreak prophylaxis may be continued for up to 6 weeks. [​11]

Renal‑Impairment Dose Adjustments

• In children with creatinine clearance of 10–30 mL/min, the AAP recommends reducing the prophylactic dose to either 30 mg once daily or 75 mg every other day for the 10‑day course (applicable to children weighing >40 kg who otherwise would receive adult dosing). [​11]

Prophylaxis vs. Treatment Regimens

• Prophylaxis uses a once‑daily dosing schedule, whereas treatment of influenza with oseltamivir requires a twice‑daily regimen. [​11]

Guideline Evidence and Updates

• The 2025 AAP Pediatrics guideline represents the most current, expert‑consensus recommendation and supersedes the older 2002 ACIP recommendation for oseltamivir prophylaxis. [​11][​12]
• No randomized controlled trials have specifically demonstrated the efficacy of oseltamivir prophylaxis in hospitalized children, highlighting an evidence gap that the AAP guideline addresses through consensus expert opinion. [​11]